| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000020957 |
| Receipt No. | R000024162 |
| Official scientific title of the study | A cross-sectional study evaluating prevalence of irritable bowel sydrome in the patients who undergo colonoscopy |
| Date of disclosure of the study information | 2016/02/09 |
| Last modified on | 2016/05/08 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | A cross-sectional study evaluating prevalence of irritable bowel sydrome in the patients who undergo colonoscopy | |
| Title of the study (Brief title) | A cross-sectional study evaluating prevalence of IBS in the patients who undergo colonoscopy | |
| Region |
|
|
| Condition | ||
| Condition | Irritable bowel syndrome | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose of this study is to investigate the prevelance of irritable bowel syndorome in the patients who undergo standard colonoscopy. |
| Basic objectives2 | Others |
| Basic objectives -Others | None |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The parcentage of patients with a diagnosis of irritable bowel syndrome using the ROME III criteria |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The patients who undergo colonoscopy | |||
| Key exclusion criteria | Patients who refuse written informed concent | |||
| Target sample size | 1000 | |||
| Research contact person | |
| Name of lead principal investigator | Fuyuki Akiko |
| Organization | Yokohama City University school of medicine |
| Division name | Department of gastroenterology and hepatology |
| Address | 3-9 Fukuura Kanazawa-ku Yokohama City |
| TEL | 045-787-2640 |
| fuyuki-sin@umin.ac.jp | |
| Public contact | |
| Name of contact person | Fuyuki Akiko |
| Organization | Yokohama City University school of medicine |
| Division name | Department of gastroenterology and hepatology |
| Address | 3-9 Fukuura Kanazawa-ku Yokohama City |
| TEL | 045-787-2640 |
| Homepage URL | |
| fuyuki-sin@umin.ac.jp | |
| Sponsor | |
| Institute | Yokohama CIty University School of Medicine Department of Gastroenterology and Hepatology |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Yokohama CIty University School of Medicine Department of Gastroenterology and Hepatology |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | The cross-sectional study
We ask patients who undergo colonoscopy to answer the questionnaire of the ROMEIII criteria. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024162 |